XenoTech Hiring, Relocating to New Global Headquarters after Revenue Growth

Excerpts from http://www.xenotechllc.com/company/news-events/press-releases/xenotech-plans-expansion-to-new-global-headquarter.aspx

Contract Research Organization XenoTech, LLC, a division of Sekisui, has announced plans to relocate into a new facility in the Kansas City metro area. The planned move will double the size of XenoTech’s global headquarters and is expected to be completed in late fall, 2015.

XenoTech experienced impressive growth during fiscal year 2014, seeing record bookings and a greater than 15% increase in revenue over 2013. This growth was not only fuelled by an increasing demand for the company’s core ADME / DMPK / DDI expertise but also an ongoing expansion of related products and services designed to maximize convenience, study consistency and efficiency for XenoTech’s customers.

XenoTech COO, Jason Neat, explained, “Relocating our headquarters both facilitates and compliments XenoTech’s dedication to expanding into natural extensions of our core ADME business. We take our reputation within the in vitro ADME-DMPK market very seriously, and we will not lose sight of our core expertise. Instead, this move allows us to grow naturally into complementing areas around our DMPK expertise, expanding our offerings to match the needs of our customers to reduce the time, expense and headache involved in bringing a drug to market.”

XenoTech hired 11 full-time staff members over the course of 2014 and is planning continued expansion of its workforce throughout the next few years.

About XenoTech
XenoTech, LLC is a global Contract Research Organization with unparalleled experience and proven expertise from discovery through clinical support, providing cell and tissue-based products, screening, radiolabeling, API manufacturing, in vitro ADMET and pharmacology, in vivo ADMET and QWBA, metabolite ID and production, bioanalytical services and consulting. XenoTech's product selection includes a wide-range of high quality standard reagents, from subcellular fractions and hepatocytes to recombinant enzymes, substrates and metabolites. The company also regularly prepares and delivers custom-designed products and services in response to client requests. For additional information, please refer to the company's website at www.xenotechllc.com.